Standard chemotherapy provides equivalent survival rate to experimental in lung cancer patients
Treatment with pemetrexed, carboplatin, and bevacizumab followed by maintenance pemetrexed and bevacizumab is no better than standard therapy with paclitaxel, carboplatin, and bevacizumab followed by bevacizumab in patients with advanced non-squamous, non-small cell lung cancer, according to Northwestern University research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. Northwestern University is home to the Robert H. Lurie Comprehensive Cancer Center.
Among the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.
This text may be reproduced or reused freely. Please credit the National Cancer Institute as the source. Any graphics may be owned by the artist or publisher who created them, and permission may be needed for their reuse.